Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $37.56.

Several equities analysts have weighed in on VRDN shares. JMP Securities lowered their price objective on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating on the stock in a research report on Wednesday, May 7th. HC Wainwright reaffirmed a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. Needham & Company LLC reissued a "buy" rating and set a $36.00 target price on shares of Viridian Therapeutics in a research report on Tuesday, May 20th. The Goldman Sachs Group cut their price objective on shares of Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Finally, Royal Bank of Canada lowered their target price on shares of Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th.

Viridian Therapeutics Trading Down 2.6%

NASDAQ VRDN traded down $0.42 on Thursday, hitting $15.67. 1,069,136 shares of the stock were exchanged, compared to its average volume of 1,178,659. Viridian Therapeutics has a 52-week low of $9.90 and a 52-week high of $27.20. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of -3.64 and a beta of 0.41. The company's 50-day moving average price is $13.23 and its two-hundred day moving average price is $16.17.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($0.95) by $0.08. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The firm had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.16 million. Viridian Therapeutics's revenue was up .0% on a year-over-year basis. Research analysts predict that Viridian Therapeutics will post -4.03 EPS for the current year.

Institutional Investors Weigh In On Viridian Therapeutics

Several large investors have recently made changes to their positions in the stock. Amalgamated Bank grew its position in Viridian Therapeutics by 49.7% in the first quarter. Amalgamated Bank now owns 2,531 shares of the company's stock valued at $34,000 after purchasing an additional 840 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Viridian Therapeutics by 1.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company's stock worth $669,000 after buying an additional 876 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Viridian Therapeutics by 2.9% during the 1st quarter. SG Americas Securities LLC now owns 31,972 shares of the company's stock worth $431,000 after buying an additional 887 shares during the last quarter. Voya Investment Management LLC lifted its stake in shares of Viridian Therapeutics by 5.1% during the 4th quarter. Voya Investment Management LLC now owns 21,397 shares of the company's stock worth $410,000 after buying an additional 1,038 shares during the last quarter. Finally, Tudor Investment Corp ET AL lifted its stake in shares of Viridian Therapeutics by 3.0% during the 4th quarter. Tudor Investment Corp ET AL now owns 38,367 shares of the company's stock worth $735,000 after buying an additional 1,106 shares during the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.